An unusual battle between two small companies over the market for a rare disease drug has now spread to Canada, where Catalyst Pharmaceuticals (CPRX) has gone to court in hopes of blocking a rival medicine sold by Jacobus Pharmaceuticals, a small, family-run company, from reaching patients.

At issue is the small, but potentially lucrative market to treat people with a rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS. Last month, Health Canada endorsed the use of the Jacobus drug, but Catalyst claims the decision was “incorrect and unreasonable” because the regulator should not have referenced its drug in a compliance notice due to data protection.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy